SWAV:NSD-Shockwave Medical Inc (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 329.51

Change

-0.49 (-0.15)%

Market Cap

USD 12.34B

Volume

0.46M

Analyst Target

USD 58.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-29 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

+2.20 (+1.70%)

USD 50.10B
ALGN Align Technology Inc

-6.76 (-2.41%)

USD 21.10B
PODD Insulet Corporation

+4.82 (+2.67%)

USD 12.65B
BRKR Bruker Corporation

-1.69 (-2.18%)

USD 11.00B
MASI Masimo Corporation

+4.46 (+3.84%)

USD 6.17B
TMDX TransMedics Group Inc

-1.21 (-0.89%)

USD 4.36B
AXNX Axonics Modulation Technologie..

-0.02 (-0.03%)

USD 3.45B
LIVN LivaNova PLC

-0.32 (-0.51%)

USD 3.36B
PRCT Procept Biorobotics Corp

-1.05 (-1.52%)

USD 3.22B
IRTC iRhythm Technologies Inc

-1.89 (-1.88%)

USD 3.08B

ETFs Containing SWAV

MNA IQ Merger Arbitrage ETF 4.35 % 0.76 %

-0.15 (-1.41%)

USD 0.27B
GRPM Invesco S&P MidCap 400 GA.. 4.08 % 0.00 %

-1.68 (-1.41%)

USD 0.39B
PINK Simplify Exchange Traded .. 3.58 % 0.00 %

-0.06 (-1.41%)

USD 0.12B
JSMD Janus Henderson Small/Mid.. 3.01 % 0.50 %

-0.71 (-1.41%)

USD 0.36B
HLTH:AU VanEck Global Healthcare .. 2.78 % 0.00 %

+0.07 (+-1.41%)

USD 0.06B
WELP:LSE HAN-GINS Indxx Healthcare.. 1.80 % 0.00 %

-1.75 (-1.41%)

USD 0.02B
WELL:PA HAN-GINS Indxx Healthcare.. 1.71 % 0.00 %

-0.03 (-1.41%)

N/A
WELL:SW HAN-GINS Indxx Healthcare.. 1.71 % 0.00 %

+0.08 (+-1.41%)

N/A
ELLE:PA Lyxor Global Gender Equal.. 0.94 % 0.00 %

-0.04 (-1.41%)

N/A
JKK iShares Morningstar Small.. 0.57 % 0.30 %

N/A

USD 0.55B
CSY8:F Credit Suisse Index Fund .. 0.54 % 0.00 %

-0.42 (-1.41%)

USD 0.55B
CSY8:XETRA Credit Suisse Index Fund .. 0.54 % 0.00 %

-0.60 (-1.41%)

USD 0.55B
USSMC:SW Credit Suisse Index Fund .. 0.54 % 0.00 %

-0.40 (-1.41%)

USD 0.46B
JKJ iShares Morningstar Small.. 0.29 % 0.25 %

N/A

USD 0.22B
FHH:CA First Trust AlphaDEX US H.. 0.00 % 0.77 %

N/A

CAD 0.01B
FXH First Trust Health Care A.. 0.00 % 0.63 %

-0.43 (-1.41%)

USD 1.25B
XHE SPDR® S&P Health Care Eq.. 0.00 % 0.35 %

-0.01 (-1.41%)

USD 0.26B
WLDS:LSE iShares MSCI World Small .. 0.00 % 0.00 %

-0.02 (-1.41%)

USD 3.80B
WSML:LSE iShares MSCI World Small .. 0.00 % 0.00 %

-0.01 (-1.41%)

USD 3.76B
WELL:LSE Hanetf Icav - Han-Gins He.. 0.00 % 0.00 %

-0.01 (-1.41%)

USD 0.02B
VOOM:XETRA Lyxor Global Gender Equal.. 0.00 % 0.00 %

-0.01 (-1.41%)

USD 0.06B
W311:XETRA HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

-0.02 (-1.41%)

USD 0.02B
FHH-F:CA First Trust AlphaDEX U.S... 0.00 % 0.00 %

+0.26 (+-1.41%)

CAD 0.01B
ISCG iShares Morningstar Small.. 0.00 % 0.00 %

-0.57 (-1.41%)

USD 0.55B
VOOM:F Lyxor Index Fund - Lyxor .. 0.00 % 0.00 %

-0.01 (-1.41%)

USD 0.06B
W311:F HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

-0.02 (-1.41%)

USD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 72.92% 93% A 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 72.92% 93% A 94% A
Trailing 12 Months  
Capital Gain 14.04% 81% B- 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.04% 81% B- 68% D+
Trailing 5 Years  
Capital Gain 743.38% 100% F 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 743.38% 100% F 97% N/A
Average Annual (5 Year Horizon)  
Capital Gain 77.59% 93% A 94% A
Dividend Return 77.59% 93% A 94% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 99.71% 28% F 16% F
Risk Adjusted Return 77.82% 99% N/A 92% A
Market Capitalization 12.34B 98% N/A 94% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.